Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply

Affiliations

¹ Department of Medicine, NAFLD Research Center, La Jolla, CA, USA.
² Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
³ Division of Gastroenterology and Hepatology, Alameda Health System, Highland Hospital, Oakland, CA, USA.
⁴ Health Economics Outcomes Research, Gilead Sciences, Foster City, CA, USA.
⁵ Chronic Disease Research Group, Minneapolis, MN, USA.
⁶ Pinnacle Clinical Research, San Antonio, TX, USA.
⁷ Department of Gastroenterology and Hepatology, Henry Ford Hospital, Wayne State University School of Medicine, Detroit, MI, USA.

Editorial

Rohit Loomba et al. Aliment Pharmacol Ther. 2020 Jun.

. 2020 Jun;51(11):1200-1201.

doi: 10.1111/apt.15724.

¹ Department of Medicine, NAFLD Research Center, La Jolla, CA, USA.
² Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
³ Division of Gastroenterology and Hepatology, Alameda Health System, Highland Hospital, Oakland, CA, USA.
⁴ Health Economics Outcomes Research, Gilead Sciences, Foster City, CA, USA.
⁵ Chronic Disease Research Group, Minneapolis, MN, USA.
⁶ Pinnacle Clinical Research, San Antonio, TX, USA.
⁷ Department of Gastroenterology and Hepatology, Henry Ford Hospital, Wayne State University School of Medicine, Detroit, MI, USA.

No abstract available

Comment on

Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
Loomba R, Wong R, Fraysse J, Shreay S, Li S, Harrison S, Gordon SC. Loomba R, et al. Aliment Pharmacol Ther. 2020 Jun;51(11):1149-1159. doi: 10.1111/apt.15679. Epub 2020 May 5. Aliment Pharmacol Ther. 2020. PMID: 32372515
Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world?
Harris R, West J, Morling JR. Harris R, et al. Aliment Pharmacol Ther. 2020 Jun;51(11):1199-1200. doi: 10.1111/apt.15714. Aliment Pharmacol Ther. 2020. PMID: 32424922 No abstract available.

1. Harris R, West J, Morling JR. Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Aliment Pharmacol Ther. 2020;51:1199-1200.
1. Loomba R, Wong R, Fraysse J, et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther. 2020;51:1149-1159.
1. Yu Y, Cai J, She Z, et al. Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases. Advanced Science. 2019;6:1801585.
1. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180-190.
1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357.